Article
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.
Journal of viral hepatitis - 1 Apr 2015
Manns M P, Fried M W, Zeuzem S, Jacobson I M, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott J A, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M
Abstract excerpt
This pooled analysis of five Phase IIb and III studies evaluated the safety and tolerability of simeprevir, a once daily, oral hepatitis C virus (HCV) NS3/4A protease inhibitor. Data were summarised for patients who received simeprevir 150 mg once daily (n = 924) or placebo (n = 540) plus pegylated interferon-α/ribavirin for 12 weeks. During the first 12 weeks of treatment, few patients discontinued simeprevir or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.